{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:57:55Z","timestamp":1790287075035,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2021-DD120822"],"award-info":[{"award-number":["RS-2021-DD120822"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023443","name":"Commercializations Promotion Agency for R&D Outcomes","doi-asserted-by":"publisher","award":["RS-2023-00233462"],"award-info":[{"award-number":["RS-2023-00233462"]}],"id":[{"id":"10.13039\/501100023443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C1003358"],"award-info":[{"award-number":["2021R1A2C1003358"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejps.2024.106921","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T18:59:49Z","timestamp":1727722789000},"page":"106921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity"],"prefix":"10.1016","volume":"203","author":[{"given":"Hyewon","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojeong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hoon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Whan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Soon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonjung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106921_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2018.12.030","article-title":"Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals","volume":"845","author":"An","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2024.106921_bib0002","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2024.106921_bib0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejmech.2018.12.039","article-title":"Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: an overview","volume":"164","author":"Banerjee","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2024.106921_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/cmdc.201200450","article-title":"Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin\u2005A","volume":"8","author":"Baud","year":"2013","journal-title":"Chem. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejps.2024.106921_bib0005","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4155\/fmc-2016-0117","article-title":"Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases","volume":"8","author":"Chakrabarti","year":"2016","journal-title":"Future Med. Chem."},{"issue":"Pt 3","key":"10.1016\/j.ejps.2024.106921_bib0006","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.ejps.2024.106921_bib0007","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/187152011795347540","article-title":"Modulation of histone acetylation by garlic sulfur compounds","volume":"11","author":"Druesne-Pecollo","year":"2011","journal-title":"Anticancer Agents Med. Chem."},{"issue":"17","key":"10.1016\/j.ejps.2024.106921_bib0008","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ejps.2024.106921_bib0009","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejps.2024.106921_bib0010","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1021\/jm5008209","article-title":"ST7612AA1, a thioacetate-\u03c9(\u03b3-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors","volume":"57","author":"Giannini","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2024.106921_bib0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"19","key":"10.1016\/j.ejps.2024.106921_bib0012","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1016\/j.bmcl.2008.08.056","article-title":"Substituted ajoenes as novel anti-cancer agents","volume":"18","author":"Hunter","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejps.2024.106921_bib0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/em.20474","article-title":"Biological properties of garlic and garlic-derived organosulfur compounds","volume":"50","author":"Iciek","year":"2009","journal-title":"Environ. Mol. Mutagen."},{"issue":"10","key":"10.1016\/j.ejps.2024.106921_bib0014","doi-asserted-by":"crossref","first-page":"e1476","DOI":"10.1038\/cddis.2014.422","article-title":"HDAC8 and STAT3 repress BMF gene activity in colon cancer cells","volume":"5","author":"Kang","year":"2014","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ejps.2024.106921_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2020.03.007","article-title":"AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation","volume":"478","author":"Li","year":"2020","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.ejps.2024.106921_bib0016","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2024.106921_bib0017","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.ejps.2024.106921_bib0018","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol Oncol"},{"issue":"9","key":"10.1016\/j.ejps.2024.106921_bib0019","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/carcin\/bgn165","article-title":"Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter","volume":"29","author":"Nian","year":"2008","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.ejps.2024.106921_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejps.2024.106921_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not be the best histone deacetylase inhibitors\u2013what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"Chem. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejps.2024.106921_bib0022","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.bmcl.2004.03.063","article-title":"Thiol-based SAHA analogues as potent histone deacetylase inhibitors","volume":"14","author":"Suzuki","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejps.2024.106921_bib0023","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrm3931","article-title":"50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond","volume":"16","author":"Verdin","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejps.2024.106921_bib0024","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0002-9440(10)63320-2","article-title":"Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues","volume":"165","author":"Waltregny","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.ejps.2024.106921_bib0025","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1096\/fj.04-2303fje","article-title":"Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility","volume":"19","author":"Waltregny","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2024.106921_bib0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2016.01.013","article-title":"Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy","volume":"109","author":"Wen","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejps.2024.106921_bib0027","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2011.06.030","article-title":"Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors","volume":"19","author":"Whitehead","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2024.106921_bib0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/med.21320","article-title":"Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy","volume":"35","author":"Zhang","year":"2015","journal-title":"Med. Res. Rev."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:17:33Z","timestamp":1778775453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724002343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"alternative-id":["S0928098724002343"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106921","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106921"}}